Drugs / PGV002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05192460 | Mar 2022 → Dec 2024 | esophageal cancer, gastric cancer, liver cancer | jianming xu | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PGV002 | “PGV002 mRNA Vaccine” NCT05192460 ↗ |
| Known as | PGV002 mRNA Vaccine | “PGV002 mRNA Vaccine” NCT05192460 ↗ |
| Modality | Messenger RNA (mRNA) | “mRNA neoantigen tumor vaccine” NCT05192460 ↗ |